Emplicure is set to be granted a patent in Japan for inhalation of pharmaceuticals

2022-03-17 07:30

Emplicure AB (publ) is set to be granted a patent by the Japan Patent Office for inhalation of pharmaceuticals.

The Japanese Patent Office has confirmed its intention to grant the patent application for inhalation of pharmaceuticals, application No 2018-545487. This means the review and examination phase has passed and all terms are fulfilled. The patent is expected to be granted within the next months, and then into 2038.

"Japan is an important market for us and the granted patent sets a solid foundation for continual product development, and to push forwards outlicensing and co-development agreements based on our proprietary bioceramic technology platforms. In December last year we received the equivalent patent for the U.S. and this Japanese patent solidifies the strength in our platform, and the potential in developing pharmaceuticals for inhalation", says Torbjorn W. Larsson, CEO of Emplicure

Torbjorn W. Larsson
Phone: +46 (0)70 747 65 99
Email: torbjorn.walkerlarsson@emplicure.com

Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on March 17, 2022 at 08:30 CET.

The following documents can be retrieved from beQuoted

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subisidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com

Do you want to know more?